Novavax Inc
NVAX
NASDAQ
Biotechnology
$8.05
USD
-0.09 (-1.11%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $1.31B
Volume 2.3M
Peer Comparison Table
(1/4) | ||||||
|---|---|---|---|---|---|---|
INBX | Inhibrx Biosciences Inc | $1.37B | - | +550.0% | - | |
GLUE | Monte Rosa Therapeutics Inc | $1.35B | - | -83.9% | - | |
AKTS | Aktis Oncology Inc | $1.33B | - | +49.9% | - | |
PURR | Hyperliquid Strategies Inc | $1.32B | - | - | - | |
JBIO | Jade Biosciences Inc | $1.32B | - | - | - | |
MNKD | MannKind Corp | $1.29B | - | +30.5% | - | |
NVAX | Novavax Inc | $1.27B | - | -61.6% | - | |
MGTX | MeiraGTx Holdings PLC | $1.22B | - | +131.1% | - | |
SVRA | Savara Inc | $1.16B | - | - | - | |
CRVS | Corvus Pharmaceuticals Inc | $1.14B | - | - | - |
Top Peer by Growth
Inhibrx Biosciences Inc
+550.0% YoY Revenue
Best 1-Year Return
Inhibrx Biosciences Inc
+348.7% Return